Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers.
+ 2 more risks
Excellent balance sheet with limited growth.
Share Price & News
How has Sunesis Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RYIP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RYIP exceeded the German Biotechs industry which returned 9% over the past year.
Return vs Market: RYIP exceeded the German Market which returned 14.4% over the past year.
Price Volatility Vs. Market
How volatile is Sunesis Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Sunesis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RYIP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RYIP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RYIP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: RYIP is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RYIP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RYIP is overvalued based on its PB Ratio (4.2x) compared to the DE Biotechs industry average (3.6x).
How is Sunesis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RYIP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RYIP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RYIP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RYIP's revenue (61.8% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: RYIP's revenue (61.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RYIP's Return on Equity is forecast to be high in 3 years time
How has Sunesis Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RYIP is currently unprofitable.
Growing Profit Margin: RYIP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RYIP is unprofitable, but has reduced losses over the past 5 years at a rate of 9.6% per year.
Accelerating Growth: Unable to compare RYIP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RYIP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: RYIP has a negative Return on Equity (-74.44%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Sunesis Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RYIP's short term assets ($40.5M) exceed its short term liabilities ($8.9M).
Long Term Liabilities: RYIP's short term assets ($40.5M) exceed its long term liabilities ($422.0K).
Debt to Equity History and Analysis
Debt Level: RYIP's debt to equity ratio (16.9%) is considered satisfactory.
Reducing Debt: RYIP's debt to equity ratio has reduced from 309.9% to 16.9% over the past 5 years.
Inventory Level: RYIP has a low level of unsold assets or inventory.
Debt Coverage by Assets: RYIP's debt is covered by short term assets (assets are 7.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RYIP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RYIP has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.2% each year.
What is Sunesis Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RYIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RYIP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RYIP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RYIP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RYIP's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dayton Misfeldt (45yo)
Mr. Dayton Misfeldt has been an Interim CEO of Sunesis Pharmaceuticals, Inc. since January 1, 2018 and as its Director since April 2009. Mr. Misfeldt serves as Managing Director and Investment Partner at B ...
|Interim CEO & Director||2.1yrs||US$574.94k||no data|
|Senior VP of Finance & Corporate Development and CFO||2.3yrs||US$501.17k||0.10% $82.5k|
|Chief Scientific Officer and Executive VP of Research & Development||3.1yrs||no data||0.036% $28.7k|
|Vice President of Quality Assurance||1.6yrs||no data||no data|
|Senior Vice President||4yrs||no data||no data|
|Senior Vice President of Commercial||0.6yrs||no data||no data|
|Executive Director of Project Management||1.6yrs||no data||no data|
|Strategic Advisor||2.1yrs||US$565.45k||no data|
Experienced Management: RYIP's management team is considered experienced (2.1 years average tenure).
|Interim CEO & Director||2.1yrs||US$574.94k||no data|
|Independent Director||13.7yrs||US$92.74k||no data|
|Director||0.4yrs||no data||no data|
|Non-Executive Chairman||16.2yrs||US$105.24k||0.0062% $4.9k|
|Independent Director||2yrs||US$276.08k||no data|
|Independent Director||8yrs||US$87.74k||0.010% $7.9k|
|Independent Director||13.7yrs||US$99.62k||no data|
|Independent Director||6.7yrs||US$110.24k||no data|
Experienced Board: RYIP's board of directors are considered experienced (9.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100.8%.
Sunesis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Sunesis Pharmaceuticals, Inc.
- Ticker: RYIP
- Exchange: DB
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$85.716m
- Listing Market Cap: US$79.425m
- Shares outstanding: 111.32m
- Website: https://www.sunesis.com
Number of Employees
- Sunesis Pharmaceuticals, Inc.
- 395 Oyster Point Boulevard
- Suite 400
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|A2ARHW||DB (Deutsche Boerse AG)||COM PAR USD0.0001 (POST REV SPLT)||DE||EUR||No data|
|SNSS||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Sep 2005|
|RYIP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2005|
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 21:22|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.